Important Information for Investors: Viatris Securities Class Action Lawsuit
New York, NY and New Orleans, LA – Kahn Swick & Foti, LLC (KSF) and its partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (Viatris or the Company) if they purchased the Company’s securities between August 8, 2024, and February 26, 2025, inclusive (the Class Period).
Background on Viatris
Viatris is a global healthcare company formed through the merger of Pfizer’s Upjohn business and Mylan N.V. The Company focuses on providing branded and generic medicines to patients worldwide. Viatris’ portfolio includes a wide range of therapeutic areas, such as cardiovascular, neurology, infectious disease, and pain management.
Securities Class Action Lawsuit
The lawsuit alleges that during the Class Period, Viatris and certain of its executives made false and misleading statements regarding the Company’s financial condition, business prospects, and compliance with regulatory requirements. Specifically, it is alleged that the Company failed to disclose material information related to certain regulatory issues, including the potential for significant delays in the approval of certain generic drugs and the potential impact on the Company’s financial results.
Impact on Individual Investors
If you purchased Viatris securities during the Class Period and wish to serve as a lead plaintiff in the securities class action lawsuit, you must file your petition with the Court by the lead plaintiff deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Impact on the World
The securities class action lawsuit against Viatris could have significant implications for the global healthcare industry. The allegations of regulatory non-compliance and financial misrepresentation could lead to increased scrutiny of similar practices by regulatory agencies and investors. Additionally, the outcome of the lawsuit could impact investor confidence in the pharmaceutical sector as a whole.
Conclusion
If you purchased Viatris securities during the Class Period and believe you have been negatively impacted by the Company’s alleged misrepresentations, you may be entitled to compensation. It is important to act quickly and file your lead plaintiff application by the June 3, 2025, deadline. For more information, contact Kahn Swick & Foti, LLC.
- Contact KSF for more information: 1-877-515-1850 or [email protected]
- Visit KSF’s website:
